Visual abstract | Ruxolitinib versus basiliximab in adult patients with steroid-refractory aGvHD

Acute graft-versus-host disease (aGvHD) occurs in approximately 30–50% of patients who receive allogeneic hematopoietic stem cell transplantation (allo-HSCT).¹

Although glucocorticoids are the standard first-line treatment, they fail to yield a response in almost 60% of patients; outlining the need for second-line treatment options.¹ The current recommended second-line treatment for steroid-refractory aGvHD is ruxolitinib, a JAK inhibitor, with basiliximab also considered a feasible salvage therapy option.¹